These preclinical results provide the basis for a novel immune-based therapeutic strategy, targeting KMO, alone or in combination with PD-L1 blockade, to restore anti-MM immune responses in patients with this malignancy [145]. This evidence concerns the gene CD274 and Miyoshi myopathy.